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Background & objectives: Subclinical adrenal insufficiency has been shown to occur in patients
with tuberculosis. Whether this insufficiency can be reversed with therapy and on long-term
follow up, is not known. We studied the effect of antituberculosis treatment (ATT) with respect
to reversal of the adrenal insufficiency, as assessed by response to standard dose
adrenocorticotropin (ACTH) stimulation test in TB patients.
Methods: One hundred and five HIV-negative tuberculosis patients were studied. Of these, 72
patients had pulmonary and 33 had extrapulmonary forms of the disease. Baseline (pre-treatment)
standard-dose ACTH stimulation test was done on all the subjects, following which, they were
put on standard antituberculosis therapy, depending on the type of disease and were followed
up for a period of 30 months. ACTH stimulation tests were performed at follow up, every 6
months.
Results: Baseline (pre-treatment) standard-dose ACTH stimulation test revealed an impaired
response in 52 of 105 patients (49.5%). At 6 months, the percentage of responders had increased
to 71 per cent with a gradual increasing trend noted thereafter. At 24 months, 31 of the 32
patients (97%) who were followed up demonstrated a normal response to ACTH stimulation.
The percentage of responders was comparable in both pulmonary [21 of 22 patients (95%)] and
extrapulmonary TB [10 of 10 patients (100%)] groups at follow up.
Interpretation & conclusion: Our study shows that nearly half of patients with active tuberculosis
had a subclinical adrenal insufficiency indicated by an impaired response to ACTH stimulation
test. This insufficiency reverse with therapy in most patients on long-term follow up.
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Tuberculosis (TB) affects about 7-8 million people
globally every year1. With the advent of the human
immunodeficiency virus (HIV) infection epidemic the
global incidence is growing at the rate of 0.4 per cent
per year. One-third of the global burden is shared by
India alone1. Worldwide, the disease stakes nearly two
million lives each year; thus underscoring its
importance as a major public health issue.
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The existence of a subclinical adrenal deficiency
in active TB has been a matter of debate in the past2,3.
Previous studies that have addressed the issue have
reported variable results ranging from the presence
of an adrenal insufficiency in 0-50 per cent of the
cases2-4 to an actual state of hypersecretion of cortisol5.
We have earlier reported an incidence of adrenal
hyporesponsiness in 49.5 per cent cases in a cohort of
97 patients with active TB4. The discrepancy in the
data is probably accounted for by the high prevalence
of malnutrition in the Indian population of patients.
This insufficiency exists in active stage of the disease
and may be present with or without evidence of
physical involvement or destruction of the glands4,
and may become important only in a stressful
situation.
Few follow up studies have been done, a limitation
with these studies was the short period of follow up,
ranging from two weeks to two months5-9. The present
study was done to determine the reversibility of the
subclinical adrenal insufficiency using standard
antituberculosis therapy and to identify a temporal
correlate, if any, with duration of therapy and reversal
of adrenal compromise.
Material & Methods
Study subjects: A total of 105 HIV-negative patients
having various forms of TB that included pulmonary
(PTB) (n=32), disseminated or miliary TB (DTB/
MTB) (n=33) and multi-drug resistant TB (MDR-TB)
(n=40) were recruited from the outpatient clinics and
wards at the All India Institute of Medical Sciences,
New Delhi during 1995-1998. The criteria applied for
diagnosing these patients were the same as those in
our previous study4. Of this cohort of 105, patients
results of cross-sectional study (n=97) have been
reported previously4. Eight new patients were
recruited. The present study describes results of
longitudinal follow up of adrenocortical function in
these 105 subjects.  Written informed consent was
obtained from all the patients participating in the
study. The Institutional Ethics Committee approved
the study.
Healthy controls: A group of 27 age-matched healthy
controls were also subjected to a baseline ACTH
stimulation test. The controls were selected from the
medical outpatient department based on normal
haemogram, normal liver and renal function tests, a
normal chest radiograph and a negative Mantoux test.
Adrenocortical reserve estimation: A standard (250
µg) dose ACTH stimulation test was performed for
estimation of the adrenal reserve. Based on the criteria
defined by Tyrell et al10, a normal response was
defined as a peak cortisol value >410 nmol/l with an
increment of >137 nmol/l. If a peak value >550 nmol/
l was obtained, the response was considered normal
regardless of the increment. The subjects were then
classified as responders and non-responders based on
the presence or absence of a normal response as
described previously4.
Treatment and follow up: All patients with PTB and
DTB/MTB received standard 4-drug anti-TB
treatment for a period of 6 months and 6-9 months
respectively. Patients with MDR-TB received second-
line anti-TB drugs for duration of 18-24 months.
All patient groups were followed up for a period
of 30 months with the ACTH stimulation test being
performed at intervals of six months during follow
up.
Statistical analysis: Data were analysed using
STATA Inc. Corp software package, College station,
Texas, USA. Paired and unpaired t-test was used for
analysis.
Results & Discussion
When compared to a group of age-matched healthy
controls, the study population showed significantly
(P<0.001) lower values for body mass index, serum
albumin and mid-arm circumference (Table I).
Prior to initiation of anti-TB treatment, 52 (49.5%)
of the 105 patients showed evidence of compromised
adrenal reserve. Of these, 16 had PTB, 17 had DTB
and 19 had MDR-TB. The percentages of non-
responders were comparable in the three groups: 50
per cent PTB, 51.6 per cent DTB and 48 per cent
MDR TB.
Thirty two patients of the initial 105 were followed
up to 24 months. With 31 of these 32 patients
demonstrating a responsive adrenocortical axis, the
percentage of responders at this stage of the follow
up had escalated to 96.87 per cent from the initial
50.5 per cent (P<0.05) (Fig.). Table II compares the
cortisol values to ACTH stimulation test across
various subgroups.
129
An analysis of the subgroups was done based on
the pulmonary, disseminated and MDR forms of the
disease (Table II). In the pulmonary TB category the
percentage of ACTH-responders increased from 50
per cent (16 of 32) at study initiation to 68.8 per cent
(22 of 32) at treatment completion (6 months). Eight
patients who were followed up to 24 months revealed
an escalation of the responders to 87.5 per cent of
8 patients (P<0.05).
In the disseminated TB group, the ACTH
responders increased from 48.4 per cent (16 of 33) at
study initiation to 75 per cent at treatment completion
(6-9 months). The ACTH-responders increased to 100
per cent at 24 months, with all 10 patients who
followed up at this period demonstrating a responsive
axis (P<0.05).
SHARMA et al: ATT IN REVERSAL OF ADRENAL INSUFFICIENCY
Table I. Baseline demographic characteristics of tuberculosis patients and normal controls
Healthy controls Tuberculosis
(n=27) group (n=105)
Age (yr) 26.9 ± 5.6 29 ± 10.2
Sex (M/F) 23/4 69/36
Duration of symptoms (wk) - 8.3 ± 128.7
BMI (kg/m2) 20.7 ± 2.5 17.6 ± 2.9*
MAC (cm) 26.3 ± 3.2 22 ± 3*
TSFT (mm) 10.3 ± 3.4 9.2 ± 3.3
ALC (mm3) 2580 ± 546 2664 ± 1199
Total serum proteins (g/dl) 8.26 ± 0.40 8 ± 0.8
Albumin (g/dl) 5.16 ± 0.57 4.2 ± 0.74*
All values except sex are presented as mean ± SD
BMI, Body mass index; MAC, mid-arm circumference; TSFT, triceps skin fold thickness; ALC, absolute lymphocyte count
*P<0.001 compared to controls
Table II. Cortisol response to ACTH testing in various subgroups
 II a. Comparison of cortisol values (n mol/l) at pre-treatment and 6 month follow up
Controls DTB PTB MDR-TB
(n=27) (n=33) (n=32) (n=40)
0 min Pre-treatment 395 ± 124 381 ± 215 392 ± 131 358 ± 138
Post-treatment 385 ± 148 462 ± 162* 352 ± 137
30 min Pre-treatment 499 ± 159 482 ± 229 455 ± 134 428 ± 178
Post-treatment 533 ± 199 549 ± 202* 471 ± 125
60 min Pre-treatment 530 ± 195 473 ± 196 477 ± 145 485 ± 172
Post-treatment 573 ± 204 567 ± 203* 539 ± 198
II b. Comparison of cortisol values (n mol/l) for the cohort present at final follow up (24 months)
DTB PTB MDR-TB
(n=10) (n=8)  (n=14)
0 min Pre-treatment 293 ± 102 385 ± 146 334 ± 148
Post-treatment 436 ± 253* 517 ± 333 442 ± 124
30 min Pre-treatment 432 ± 163 477 ± 139 417 ± 194
Post-treatment 653 ± 192** 807 ± 266** 693 ± 137**
60 min Pre-treatment 452 ± 159 487 ± 140 378 ± 368
Post-treatment 755 ± 198** 785 ± 252** 844 ± 214**
DTB, Disseminated TB; PTB, pulmonary TB; MDR-TB, multi-drug resistant TB
*P<0.05, **<0.01 compared to pre-treatment
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In the MDR-TB group (n=40), 52 per cent patients
were ACTH responders at initiation, 20 patients
followed up at treatment completion (18 months), of
these 85 per cent (n=17) demonstrated a responsive
axis. All 14 patients who were followed at 24 months
demonstrated ACTH responsiveness i.e., 100 per cent
(P<0.05).
A standard dose (250 µg) ACTH stimulation test
was conducted in all patients at the time of inclusion
and 6 monthly thereafter for a period of 2.5 yr. The
reason for selecting a standard 250 µg dose test as
against a low dose was the lack of adequate evidence
in support of the low dose test at the time we initiated
our study, and the recent recommendations also
suggested the need for cautious interpretation of the
low dose test11. Using the criteria suggested by Tyrell
et al10, we classified patients into responders and non-
responders and based our subsequent data analysis
according to this stratification. This classification on
the basis of ACTH responsiveness and adrenal reserve
function appeared clinically more relevant than the
actual levels of basal and peak serum cortisol. The
longitudinal follow up enabled us to identify trends in
the adrenal functional reserve with respect to therapy.
However, owing to the large sample size (n=105)
coupled with the long-term follow up, significant
attrition was a problem (n=16 at 30 months). In order
to eliminate attrition bias we interpreted results at 24
months (n=32).
We noted a near total reversal in our study group
as the responders increased from 49.5  to nearly 97
per cent after a follow up of two years. Similar results
have been described previously in studies with a small
number of cohorts7-9. The study by Ellis and Tayoub
in 41 subjects7 noted a drop in the non-responders from
55 (pre-treatment) to 30 per cent after two weeks of
therapy. Barnes et al9 noted a decrease in the negative
responders following one month of therapy, however,
the incidence of adrenal compromise reported was very
small (8% of the study population of 90 patients).
Fig. Responsiveness of the adrenocortical axis with respect to institution of chemotherapy in tuberculosis patients. The percentage
of responders escalated from 49.5 per cent (0 months) to 96.87 per cent (24 months).
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Chan et al8 reported a reversal of all the 41 per cent
ACTH non-responders (pre-treatment) in a group of
39 patients, when re-tested at 2 months of treatment.
The limitation of these studies has been the short-term
follow up. A study published in 1996 by Gulmez et
al12, in a group of 11 patients, showed a decrease in
the size of the adrenals on CT scan after receiving 8
months of ATT. Though ACTH responsiveness was
not tested at the 8 month follow up, a reduction
in gland size on CT imaging suggested a reversal
of adrenal pathology following appropriate
chemotherapy, and thus supports our hypothesis.
It is thus evident that in comparison to the previous
studies, a near-complete reversal of the adrenal
hyporesponsiveness has been noted in our study. This
may be attributable to the 24 month follow up period.
This long-term follow up also enabled us to make an
interesting observation. Maximal reversal of the non-
responders was seen in the initial 6 months of therapy,
which is the time for complete cure of active disease
in majority of the patients with pulmonary TB. This
might suggest that it was perhaps the impact of the
active disease process (in the setting of a malnourished
state) that induced the adrenal insufficiency.
Thus, it may be concluded that the subclinical
adrenal compromise in patients with active
tuberculosis affects a sizeable portion of the TB
patients with active disease in India. The distribution
of non-responders was found to be equal in various
forms of the disease. This abnormality in adrenal
function was reversible and appeared to resolve with
chemotherapy, in all subsets of patients, affected with
various forms of the disease. The reversal seen was
maximal following six months of chemotherapy and
correlated well with cure of disease in most patients.
This subclinical insufficiency may become important
and clinically significant in acute stressful situations.
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